An American success story

2006 Forbes Platinum 400 list of America's Best Big Companies

INVITROGEN was founded in 1987 and went public in 1999. Two years after its IPO, Invitrogen stock had gone from $15 to $75 a share, a 500% increase. From 1996 to 2001, the company enjoyed a net revenue growth rate of 70% and pro-forma net income growth of 122%. Invitrogen has operations in 24 countries and regions, and in 2005, our revenue has surpassed $1.2 billion.

A global leading company in Life Science

Invitrogen is one of the world's top leading biotech companies and a key partner in the global life science community.

To discover how life works is the greatest scientific endeavor of our era, holding promise of fundamental improvement in the human condition. Our Quest is to accelerate this search through innovations in science and technologies that expand biological understanding.

With over 4,800 employees, our efforts are focused on breakthrough innovations in all major areas of biological discovery, including functional genomics, proteomics, bioinformatics, and cell biology. Invitrogen provides essential life science technologies for disease research, drug discovery, and commercial bio-production.

We offer more than 15,000 products and services to scientists conducting fundamental research, developing new medicines and creating next-generation clinical tests. Around the world every day, our people and our products are working to better the human condition and ultimately improve the living experience.

A fast growth in Asia-Pacific

With Asia Pacific headquarter in Shanghai, we have over 500 people in sales, marketing, R&D, operation located in major cities in Asia Pacific including Shanghai, Beijing, Guangzhou, Hongkong, Taiwan, Japan, Singapore, New Zealand, Australia, India and Korea.

A click to accelerate discovering the life and yourself

Search Invitrogen Asia-Pacific Employment Opportunities

www.invitrogen.com